SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oxford GlycoSciences Plc
An SI Board Since January 2000
Posts SubjectMarks Bans
469 13 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
394I'd like to complement Schwab's eNotice service. They made it very convkeokalani'nui-3/10/2003
393I forgot...... BRAVO!!!....... >> adjournment to a later date to be adscaram(o)uche-3/6/2003
392>> It's the protein/target patents I'm worrying about. << Wscaram(o)uche-3/6/2003
391<i>the OGSI proteomics patents are use patents.</i> Granted, and thnigel bates-3/6/2003
390Oxford Glycosciences Plans To Adjournment Meeting Thursday March 6, 9:10 am ET scaram(o)uche-3/6/2003
389Nigel: One would need look at the examples and claims. They were trying to getscaram(o)uche-3/6/2003
388United States Patent 6,048,850 Young ,   et al. April 11, 2000 --------nigel bates-3/6/2003
387To what extent does the decision on the University of Rochester patent affect thnigel bates-3/6/2003
386Expert Opin Investig Drugs 2003 Feb;12(2):273-81 Substrate reduction therapy: scaram(o)uche-3/5/2003
385just parking stuff that might help to understand and frame some side effects???.scaram(o)uche-3/5/2003
384looks like about what might have been expected..... good news?....... Messagscaram(o)uche-3/4/2003
383mcknuckles from Berlin is usually a reliable source. But, who cares? GEN isn&#scaram(o)uche-3/4/2003
382I tried but could not verify this: Not quite Cerezyme but nice. by: fatty_mcknukeokalani'nui-3/4/2003
381OGSI is one of the top five proteomics efforts and possesses i.p. that is often scaram(o)uche-3/4/2003
380<i>it couldn't have been done worse</i> I'm sure there are nigel bates-3/4/2003
379urrrrrrrrgggghhhhhhh............. it couldn't have been done worse!scaram(o)uche-3/4/2003
378I'm an absolute idiot," says (VGNX BoD), chief executive of Variagenicsrkrw-3/4/2003
377>> The newly formed company from the merger, Nuvelo, has halted developmenscaram(o)uche-3/4/2003
376The biotech dilemma: cash-rich, product-poor Tuesday March 4, 12:38 am ET By Vinigel bates-3/4/2003
375Actelion Presents a Full and Promising Clinical Pipeline -- Strong R&D as Bascaram(o)uche-3/4/2003
374Several press stories this weekend that CAT to increase its bid, and that CLL winigel bates-3/3/2003
373Actelion Starts Launch of Zavesca(R) (miglustat) in the European Union Monday Mascaram(o)uche-3/3/2003
372Abbott Laboratories Initiates Clinical Trials to Explore Use of HUMIRA(TM) (adalscaram(o)uche-3/3/2003
371Actelion Starts Launch of Zavesca in the European Union; Patients in U.K. First scaram(o)uche-3/3/2003
370One thing militating against a cash offer (possibly) is the cost basis of the twnigel bates-2/27/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News